美国Epitomics 
美国Epitomics公司成立于2001年9月，与加州大学旧金山分校(UCSF)及芝加哥LOYOLA大学联手开发出新型杂交瘤技术，拥有兔单克隆抗体（RabMabs）技术的全球专利，是国际上唯一一家拥有兔类单抗技术的生物技术公司。目前，利用此技术开发生产的高质量兔单抗产品，已广泛应用于科研和诊断领域。

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics.

Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the Company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle.

The Company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The Company is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.